Wall Street Zen upgraded shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.
Other research analysts also recently issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Friday, October 23rd. Piper Sandler reiterated an “overweight” rating on shares of Orchestra BioMed in a report on Thursday, October 15th. B. Riley Financial lifted their price objective on shares of Orchestra BioMed from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Weiss Ratings raised shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Finally, BTIG Research upped their target price on shares of Orchestra BioMed from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Orchestra BioMed currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.29.
View Our Latest Analysis on OBIO
Orchestra BioMed Trading Down 1.8%
Shares of Orchestra BioMed stock opened at $7.12 on Friday. The company has a debt-to-equity ratio of 4.58, a current ratio of 7.25 and a quick ratio of 8.24. Orchestra BioMed has a 52 week low of $3.46 and a 52 week high of $7.45. The stock has a 50 day moving average price of $5.90 and a two-hundred day moving average price of $4.64.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.10. Orchestra BioMed had a negative return on equity of 186.93% and a negative net margin of 182.50%. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.13 million. Sell-side analysts forecast that Orchestra BioMed will post -1.46 earnings per share for the current year.
Insider Activity at Orchestra BioMed
In related news, insider Darren Sherman sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $4.94, for a total transaction of $74,100.00. Following the completion of the sale, the insider owned 1,134,402 shares in the company, valued at approximately $5,603,945.88. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David P. Hochman acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were bought at an average price of $4.79 per share, with a total value of $47,900.00. Following the acquisition, the insider directly owned 1,070,746 shares of the company’s stock, valued at $5,128,873.34. The trade was a 0.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 58,000 shares of company stock valued at $288,560 and sold 45,000 shares valued at $255,600. 7.50% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Orchestra BioMed during the 2nd quarter valued at approximately $10,832,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $2,771,000. Rice Hall James & Associates LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $1,830,000. Goldman Sachs Group Inc. boosted its stake in Orchestra BioMed by 112.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 382,160 shares of the company’s stock worth $2,377,000 after purchasing an additional 202,554 shares during the period. Finally, Knott David M Jr boosted its stake in Orchestra BioMed by 1.5% in the 1st quarter. Knott David M Jr now owns 253,651 shares of the company’s stock worth $1,078,000 after purchasing an additional 3,651 shares during the period. 53.20% of the stock is currently owned by hedge funds and other institutional investors.
Orchestra BioMed Company Profile
Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company’s lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.
See Also
- Five stocks we like better than Orchestra BioMed
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
